Rinhepa 25K/5Ml Inj belongs to a class of drugs called anticoagulants or blood thinners. Rinhepa 25K/5Ml Inj is primarily used to prevent and treat deep vein thrombosis (blood clots in leg veins), pulmonary embolism (blood clots in the lung), stroke, Transient ischaemic attack (TIA), and heart attacks. Deep vein thrombosis is a medical condition in which blood clots form in deep veins, usually in the legs. Pulmonary embolism is a condition in which a blood clot blocks the arteries in the lungs. A stroke is a condition where a blood clot restricts the flow of blood to your brain, causing brain cells to die and possibly resulting in permanent brain damage or death. Transient ischaemic attack (TIA) is a condition also called mini-strokes. These have similar symptoms to a stroke, but the effects usually last less than 24 hours. Heart attack is a condition where a blood clot blocks a blood vessel supplying your heart, starving it of oxygen and causing chest pain and sometimes death.

Blood clots are formed to stop bleeding that occurs due to tissue injury. Though blood clots are useful to stop bleeding, they may be harmful when abnormally formed within blood vessels as they block blood vessels and inhibit blood flow to essential organs such as the brain, heart, or lungs. Rinhepa 25K/5Ml Inj works by inhibiting the production of fibrin (a protein that binds platelets together and forms a clot), preventing blood clot formation.

Rinhepa 25K/5Ml Inj will be administered by a healthcare professional; do not self-administer. Some people may experience haemorrhage, thrombocytopenia (low platelets), hypersensitivity reactions, and elevations of liver enzyme (aminotransferase) levels. Most of these side effects of Rinhepa 25K/5Ml Inj do not require medical attention and gradually resolve over time. However, if the side effects persist or worsen, please consult your doctor.

If you are known to be allergic to Rinhepa 25K/5Ml Inj or any other medicines, please tell your doctor. It is not known whether Rinhepa 25K/5Ml Inj harms the baby or passes into breast milk in pregnancy and breastfeeding state. If you are pregnant or breastfeeding, it is advised to consult a doctor before using Rinhepa 25K/5Ml Inj. Rinhepa 25K/5Ml Inj is not recommended for children below 2 months of age. If you have diabetes, kidney or liver problems, bleeding problems, or are aged above 60 years, inform your doctor before taking Rinhepa 25K/5Ml Inj.

Rinhepa 25K/5Ml Inj is primarily used to prevent and treat blood clots by inhibiting the production of fibrin (a protein that binds platelets together and forms a clot). Rinhepa 25K/5Ml Inj also reduces the risk of blood clots during surgeries (like heart surgery). Rinhepa 25K/5Ml Inj is used as an anticoagulant in blood transfusion and in a dialysis procedure.

Use Rinhepa 25K/5Ml Inj cautiously in conditions with increased risk of bleeding. Use of name contraindicated in patients with HIT - Heparin-induced thrombosis (the abnormal formation of blood clots inside a blood vessel) and HITT (heparin-induced thrombocytopenia and thrombosis) might occur. Monitoring of blood coagulation tests like platelet count and haematocrit should be done in all patients receiving Rinhepa 25K/5Ml Inj. Patients should inform the doctor that they are receiving Rinhepa 25K/5Ml Inj before any surgery is scheduled.